Halcyon Management Partners Lp increased St Jude Med Inc (STJ) stake by 9.16% reported in 2016Q4 SEC filing. Halcyon Management Partners Lp acquired 27,773 shares as St Jude Med Inc (STJ)’s stock rose 0.04%. The Halcyon Management Partners Lp holds 330,872 shares with $26.53M value, up from 303,099 last quarter. St Jude Med Inc now has $ valuation. It is 0.00% or $0 reaching $0 per share. It is down 4.08% since May 24, 2016 and is uptrending. It has underperformed by 2.69% the S&P500.
Analysts expect Enzymotec Ltd (NASDAQ:ENZY) to report $0.02 EPS on May, 18.They anticipate $0.04 EPS change or 66.67% from last quarter’s $0.06 EPS. ENZY’s profit would be $493,954 giving it 108.75 P/E if the $0.02 EPS is correct. After having $-0.13 EPS previously, Enzymotec Ltd’s analysts see -115.38% EPS growth. The stock increased 8.07% or $0.65 on April 13, reaching $8.7. About shares traded. Enzymotec Ltd (NASDAQ:ENZY) has risen 14.47% since September 8, 2016 and is uptrending. It has outperformed by 7.70% the S&P500.
Among 3 analysts covering Enzymotec (NASDAQ:ENZY), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Enzymotec had 4 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Enzymotec Ltd (NASDAQ:ENZY) earned “Outperform” rating by Wells Fargo on Thursday, August 13.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The company has market cap of $214.87 million. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. It currently has negative earnings. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment.